Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
UK will offer under-30s alternative to AZ’s COVID jabThe UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca Share XUK will offer under-30s alternative to AZ’s COVID jabhttps://pharmaphorum.com/news/uk-will-offer-under-30s-alternative-to-azs-covid-jab/
Novartis expands in radio-oncology again with $1.3bn Artios allianceIn its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus Share XNovartis expands in radio-oncology again with $1.3bn Artios alliancehttps://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/
Paediatric trial of AZ COVID jab ‘halted as a precaution’Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a Share XPaediatric trial of AZ COVID jab ‘halted as a precaution’https://pharmaphorum.com/news/paediatric-trial-of-az-covid-jab-halted-as-a-precaution/
Genmab CEO discusses repurposing cancer treatmentsGenmab’s CEO Jan van de Winkel has said he would consider spinning out a smaller autoimmune diseases biotech, Share XGenmab CEO discusses repurposing cancer treatmentshttps://pharmaphorum.com/news/genmab-could-spin-out-autoimmune-disease-unit-says-ceo-goes-with-feature/
FDA green lights Oxehealth vital signs monitoring softwareUK digital health company Oxehealth has claimed FDA approval for software that can be used to remotely measure Share XFDA green lights Oxehealth vital signs monitoring softwarehttps://pharmaphorum.com/news/fda-green-lights-oxehealth-vital-signs-monitoring-software/
Could Moderna shot save UK’s under-50s COVID vaccination push?People in the UK will start receiving doses of Moderna’s COVID-19 vaccine in around two weeks’ time, according Share XCould Moderna shot save UK’s under-50s COVID vaccination push?https://pharmaphorum.com/news/could-moderna-shot-save-uks-under-50s-covid-vaccination-push/
Acadia puts blame on FDA as Nuplazid rejected for dementiaAcadia Pharmaceuticals is butting heads with US regulators again, this time over the FDA’s decision to reject its Share XAcadia puts blame on FDA as Nuplazid rejected for dementiahttps://pharmaphorum.com/news/acadia-blame-fda-nuplazid-rejected-dementia/
